{"id": "62004357c9dfcb9c09000015", "question": "Does \u03b1CGRP have amyloidogenic properties?", "answer": "In this work, we investigated the amyloidogenic profile of \u03b1CGRP, a 37-residue-long peptide hormone, utilizing both biophysical experimental techniques and Molecular Dynamics simulations [29501724] The \u03b1CGRP polymerization was found to be amyloidogenic, with the formation of amyloid fibrils and aggregates [32093040] This suggests that \u03b1CGRP may have potential as a therapeutic target for neurodegenerative diseases such as Alzheimer's and Parkinson's [20360050]", "pmids": ["29501724", "32093040", "20360050"], "pmid_titles": {"29501724": "(No title fetched)", "32093040": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["33023198", "29501724", "17662457", "23551149", "37905874", "19363993", "21624562", "20360050", "20826658", "15014128", "22122056", "21764791", "37264659", "29698650", "32093040", "28922609", "23293020", "23510020", "15649697", "17244848"], "topk_titles": {"33023198": "(No title fetched)", "29501724": "(No title fetched)", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "23551149": "(No title fetched)", "37905874": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21624562": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "22122056": "(No title fetched)", "21764791": "Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.", "37264659": "(No title fetched)", "29698650": "(No title fetched)", "32093040": "(No title fetched)", "28922609": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "23510020": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "17244848": "Chronic distress, age-related neuropathology, and late-life dementia."}, "gold_ideal": ["Yes. \u03b1CGRP, a 37-residue-long peptide hormone, is a novel amyloidogenic member of the CGRP family", "Yes, it has amyloidogenic properties. It is a member of the CGRP family."], "gold_exact": ["yes"]}
{"id": "6402c910201352f04a00000c", "question": "Can losartan reduce brain atrophy in Alzheimer's disease?", "answer": "Question: Can losartan reduce brain atrophy in Alzheimer's disease? [34687634] : [12345678] INTERPRETATION: 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease [17883890] Interpretation: Losartan was well tolerated but not effective in reducing brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease [23624169]", "pmids": ["34687634", "17883890", "23624169"], "pmid_titles": {"34687634": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "23624169": "(No title fetched)"}, "topk_used": ["34687634", "25871773", "23624169", "17883890", "15649697", "23293020", "24633805", "21624562", "15783264", "19278690", "20929585", "21705182", "22536363", "2107926", "23597030", "20154508", "35558050", "24983746", "8237620", "18620875"], "topk_titles": {"34687634": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23624169": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24633805": "(No title fetched)", "21624562": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "21705182": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "35558050": "(No title fetched)", "24983746": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "gold_ideal": ["No. 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease."], "gold_exact": ["no"]}
{"id": "64040edf201352f04a000011", "question": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?", "answer": "Question: Based on clinical trial data, can semagacestat delay cognitive impairment for people at risk for Alzheimer's disease? [31738372] (each starts with PMID): [12345678] INTERPRETATION: Semagacestat did not delay the onset of mild cognitive impairment [34146512] [12345678] abstract abstract INTERPRETATION: Semagacestat did not delay the onset of mild cognitive impairment [17182990]", "pmids": ["31738372", "34146512", "17182990"], "pmid_titles": {"31738372": "(No title fetched)", "34146512": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment."}, "topk_used": ["34146512", "29507718", "15783264", "37943150", "20413854", "17182990", "29441009", "21971452", "31738372", "19585948", "31574510", "19278690", "21705182", "24983746", "22546352", "21905097", "36281662", "25203109", "16974109", "21996556"], "topk_titles": {"34146512": "(No title fetched)", "29507718": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37943150": "(No title fetched)", "20413854": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "31738372": "(No title fetched)", "19585948": "Novel strategies for the prevention of dementia from Alzheimer's disease.", "31574510": "(No title fetched)", "19278690": "(No title fetched)", "21705182": "(No title fetched)", "24983746": "(No title fetched)", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "21905097": "Personality changes in Alzheimer's disease: a systematic review.", "36281662": "(No title fetched)", "25203109": "(No title fetched)", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly."}, "gold_ideal": ["No. Pioglitazone did not delay the onset of mild cognitive impairment."], "gold_exact": ["no"]}
{"id": "61fa941ec9dfcb9c09000005", "question": "Should Intepirdine be used for Alzheimer's disease?", "answer": "Yes, Intepirdine is not currently approved for use in treating Alzheimer's disease [20154508] The available evidence suggests that it does not affect the main neuropathological hallmarks of the disease, including senile plaques and neurofibrillar tangles [17182990] However, preclinical animal studies have shown that human anti-amyloid-beta immunization does not simply clear amyloid from the Alzheimer's disease brain, but reduces some of the neuronal alterations that characterize Alzheimer's disease [20360050]", "pmids": ["20154508", "17182990", "20360050"], "pmid_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["23334070", "10510805", "7510447", "23624169", "21624562", "18620875", "7579023", "24633805", "24983746", "21705182", "20360050", "20154508", "29441009", "17182990", "19164222", "37943150", "23527322", "35558050", "37490245", "37389302"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "23624169": "(No title fetched)", "21624562": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "24633805": "(No title fetched)", "24983746": "(No title fetched)", "21705182": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "29441009": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "37943150": "(No title fetched)", "23527322": "(No title fetched)", "35558050": "(No title fetched)", "37490245": "(No title fetched)", "37389302": "(No title fetched)"}, "gold_ideal": ["No. In a phase 3 clinical trial Intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild-to-moderate Alzheimer's disease dementia patients."], "gold_exact": ["no"]}
{"id": "65ce88b71930410b13000001", "question": "Is Lecanemab approved for Alzheimer\u2019s Disease?", "answer": "Yes, Lecanemab has been recently approved by the FDA for the treatment of Alzheimer's disease [36931947] The [36931947] states that Lecanemab has been approved for this indication [37479527] The second [37682322], which discusses the pioneering nature of Lecanemab, supports this claim [37682322]", "pmids": ["36931947", "37479527", "37682322"], "pmid_titles": {"36931947": "(No title fetched)", "37479527": "Lecanemab: Looking Before We Leap.", "37682322": "(No title fetched)"}, "topk_used": ["37357276", "37927263", "37902139", "37682322", "37414156", "37060386", "37831471", "37676096", "36931947", "38021811", "38095822", "37955845", "37490245", "37334596", "36856953", "37479527", "37045461", "23334070", "37389302", "37639602"], "topk_titles": {"37357276": "(No title fetched)", "37927263": "(No title fetched)", "37902139": "(No title fetched)", "37682322": "(No title fetched)", "37414156": "(No title fetched)", "37060386": "(No title fetched)", "37831471": "(No title fetched)", "37676096": "(No title fetched)", "36931947": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "38095822": "(No title fetched)", "37955845": "(No title fetched)", "37490245": "(No title fetched)", "37334596": "(No title fetched)", "36856953": "(No title fetched)", "37479527": "Lecanemab: Looking Before We Leap.", "37045461": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37389302": "(No title fetched)", "37639602": "(No title fetched)"}, "gold_ideal": ["Yes. Lecanemab (Leqembi\u00ae) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment due to AD or mild AD dementia) with confirmed brain amyloid pathology."], "gold_exact": ["yes"]}
{"id": "66097092fdcbea915f000010", "question": "Amyloid-\u03b2 is associated with what diseases?", "answer": "Amyloid-\u03b2 is associated with Alzheimer's disease and cerebral amyloid angiopathy, as well as with other biomarkers indicative of early Alzheimer's disease in normal older people [26614753] These highly ordered protein aggregates have been, for a long time, mainly associated with human neurodegenerative diseases such as Alzheimer's disease [32093040]", "pmids": ["26614753", "32093040"], "pmid_titles": {"26614753": "(No title fetched)", "32093040": "(No title fetched)"}, "topk_used": ["25783987", "33513738", "26614753", "38075821", "37556728", "37905874", "36302506", "35892582", "36281662", "32341983", "32093040", "22957288", "37652560", "36687366", "37943150", "37264659", "29574591", "14572915", "35558050", "37489069"], "topk_titles": {"25783987": "(No title fetched)", "33513738": "(No title fetched)", "26614753": "(No title fetched)", "38075821": "(No title fetched)", "37556728": "(No title fetched)", "37905874": "(No title fetched)", "36302506": "(No title fetched)", "35892582": "(No title fetched)", "36281662": "(No title fetched)", "32341983": "(No title fetched)", "32093040": "(No title fetched)", "22957288": "Amyloid \u03b2-Related Angiitis Causing Coma Responsive to Immunosuppression.", "37652560": "(No title fetched)", "36687366": "(No title fetched)", "37943150": "(No title fetched)", "37264659": "(No title fetched)", "29574591": "(No title fetched)", "14572915": "(No title fetched)", "35558050": "(No title fetched)", "37489069": "(No title fetched)"}, "gold_ideal": ["Amyloid-\u03b2 is associated with Alzheimer's disease as well as many other neurodegenerative diseases like Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration and progressive supranuclear palsy These proteins have also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes", "Amyloid-\u03b2 (A\u03b2) is a peptide with 38-42 amino acids associated with the pathogenesis of Alzheimer's disease (AD). The most common form, A\u03b242, is the most neurotoxic.", "Amyloid-\u03b2 is associated with Alzheimer's Disease and cerebral amyloid angiopathy.", "Amyloid-\u03b2 is associated with Alzheimer's disease, amyloid-\u03b2-induced neurotoxicity and neurodegeneration, and other diseases.", "Amyloid-\u03b2 is associated with Alzheimer's disease and cerebral amyloid angiopathy.", "Amyloid-\u03b2 is associated with Alzheimer's disease, cerebral amyloid angiopathy, and AD.", "Amyloid-\u00ce\u00b2 (A\u00ce\u00b2) is associated with Alzheimer's disease (AD) and is known to promote chronic inflammatory responses in the brain. Additionally, A\u00ce\u00b2 accumulation is also found in age-related macular degeneration (AMD) and glaucoma.", "Amyloid-\u00ce\u00b2 is associated with Alzheimer's disease and age-related macular degeneration.", "Amyloid-\u03b2 is primarily associated with Alzheimer's disease and cerebral amyloid angiopathy.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and others.", "Amyloid-\u03b2 is associated with diseases such as Alzheimer's disease, Parkinson's disease, and type II diabetes, among others.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, and other amyloid diseases.", "Amyloid-\u03b2 is associated with Alzheimer's disease, multiple sclerosis, and other neurodegenerative diseases.", "\nAmyloid-\u03b2 is associated with Alzheimer's disease, Down syndrome, Parkinson's disease, and certain types of cancer. (Note: The role of amyloid-\u03b2 in Parkinson's disease and cancer is less clear.)", "Amyloid is associated with various diseases such as Alzheimer's disease, Parkinson's disease, type II diabetes, prion diseases, neurodevelopmental and neurodegenerative disorders, metabolic disorders, and certain types of cancer.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral scler", "Amyloid-\u03b2 is associated with amyotrophic lateral sclerosis, cardiovascular disease, multiple system atrophy, progressive supranuclear palsy, cancer, traumatic brain injury.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cardiovascular disease, cancer, traumatic brain injury, age-related macular degeneration, and glaucoma.", "Amyloid-\u03b2 has been associated with neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, it has been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes", "Amyloid-\u03b2 is associated with amyotrophic lateral sclerosis, cardiovascular disease, Alzheimer's disease, Parkinson's disease, cancer, traumatic brain injury, Glaucoma, and age-related macular degeneration.", "Amyloid-\u03b2 (A\u03b2) has been associated with several neurological diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, A\u03b2 has also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with several neurodegenerative diseases including Alzheimer's disease (AD), Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP) and progressive supranuclear palsy.", "Amyloid-\u03b2 is associated with a range of diseases including Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-beta is associated with several diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with neurodegenerative diseases such as Alzheimer's disease, Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy.", "Amyloid-\u03b2 has been implicated in several neurodegenerative diseases beyond Alzheimer's disease, including Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), and progressive supranuclear palsy. Additionally, research has shown that amyloid-\u03b2 may play a role in other neurological conditions such as Parkinson's disease and amyotrophic lateral sclerosis, as well as in non-neurological disorders like cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 (A\u03b2) is associated with several diseases beyond Alzheimer's disease, including Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP), and progressive supranuclear palsy (PSP). A\u03b2 deposition has also been linked to other neurological diseases, such as Parkinson's disease, amyotrophic lateral sclerosis, and retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, A\u03b2 has been implicated in cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cardiovascular disease, cancer, traumatic brain injury, Glaucoma, and age-related macular degeneration.", "Amyloid-beta (A\u03b2) is associated with various neurodegenerative diseases, including Alzheimer's disease (AD), Lewy body disease (LBD), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP), Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, and age-related macular degeneration. A\u03b2 has also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-beta is associated with a range of diseases, primarily neurodegenerative and retinal disorders. It is most notably linked to Alzheimer's disease but also connected to other conditions such as Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, and age-related macular degeneration.", "Amyloid-\u03b2 is associated with neurodegenerative diseases such as Alzheimer's disease, Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy. It has also been implicated in other conditions including Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with neurodegenerative diseases beyond Alzheimer's disease, including Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy."], "gold_exact": [["Alzheimer's disease"], ["Lewy Body diseasse"], ["frontotemporal lobar degeneration"], ["Progressive Supranuclear palsy"], ["Cardiovascular disease"], ["Traumatic brain injury"], ["Diabetes"], ["Parkinson's disease"], ["age-related macular degeneration"], ["Glaucoma"], ["amyotrophic lateral sclerosis,"]]}
{"id": "65cfa6201930410b1300000e", "question": "Is Patisiran used for Transthyretin Cardiac Amyloidosis?", "answer": "Question: Is Patisiran used for Transthyretin Cardiac Amyloidosis? [37888916] : 1 [37490245] Yes, Patisiran is a disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted [33841597]", "pmids": ["37888916", "37490245", "33841597"], "pmid_titles": {"37888916": "(No title fetched)", "37490245": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["37456349", "37888916", "33841597", "37599395", "36336119", "28893208", "37288260", "28646538", "28922609", "19363993", "34315986", "29247073", "33023198", "37905874", "21624562", "28920433", "37639602", "22815077", "26243339", "37490245"], "topk_titles": {"37456349": "(No title fetched)", "37888916": "(No title fetched)", "33841597": "(No title fetched)", "37599395": "(No title fetched)", "36336119": "(No title fetched)", "28893208": "(No title fetched)", "37288260": "(No title fetched)", "28646538": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "34315986": "(No title fetched)", "29247073": "(No title fetched)", "33023198": "(No title fetched)", "37905874": "(No title fetched)", "21624562": "(No title fetched)", "28920433": "(No title fetched)", "37639602": "(No title fetched)", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "26243339": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["Yes. Patisiran can be used for Transthyretin Cardiac Amyloidosis"], "gold_exact": ["yes"]}
{"id": "660d7324fdcbea915f000040", "question": "How many people affected by Parkinson's Disease develop dementia?", "answer": "The diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by magnetic resonance imaging and positron emission tomography (PET) by using [(18)F]fluorodeoxyglucose (FDG) [21624562] The diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by magnetic resonance imaging and positron emission tomography (PET) by using [(18)F]fluorodeoxyglucose (FDG) [17182990] The diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by magnetic resonance imaging and positron emission tomography (PET) by using [(18)F]fluorodeoxyglucose (FDG) [20929585]", "pmids": ["21624562", "17182990", "20929585"], "pmid_titles": {"21624562": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy."}, "topk_used": ["8237620", "23567438", "21971452", "21624562", "17244848", "35558050", "17182990", "19278690", "17303592", "21996556", "28272510", "21783505", "23597030", "29441009", "20929585", "14699432", "18816693", "22009441", "1406817", "24075740"], "topk_titles": {"8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "23567438": "(No title fetched)", "21971452": "(No title fetched)", "21624562": "(No title fetched)", "17244848": "Chronic distress, age-related neuropathology, and late-life dementia.", "35558050": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "19278690": "(No title fetched)", "17303592": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "28272510": "(No title fetched)", "21783505": "(No title fetched)", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "29441009": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "14699432": "Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.", "18816693": "(No title fetched)", "22009441": "(No title fetched)", "1406817": "A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.", "24075740": "(No title fetched)"}, "gold_ideal": ["Approximately a quarter of people affected by Parkinson's disease develop Parkinsonn's disease dementia.", "About 26.3% of individuals with Parkinson's Disease develop Parkinson's Disease Dementia (PDD), indicating a significant concern for those affected. However, this number may underestimate cognitive decline cases as not all are classified as PDD; other forms such as Lewy body dementia or Alzheimer's disease can also occur in these patients."], "gold_exact": [["25%"]]}
{"id": "6616a122fdcbea915f000058", "question": "Has statin use been associated with a higher risk of dementia?", "answer": "Question: Has statin use been associated with a higher risk of dementia? [24681022] : [12345678] Higher potency and longer cumulative duration of statin use were required for reducing the risk of incident dementia in male patients than in female patients [30337635] [24681022] Higher potency and longer cumulative duration of statin use were required for reducing the risk of incident dementia in male patients than in female patients [30087076]", "pmids": ["24681022", "30337635", "30087076"], "pmid_titles": {"24681022": "(No title fetched)", "30337635": "(No title fetched)", "30087076": "(No title fetched)"}, "topk_used": ["24681022", "30087076", "30337635", "29507718", "16009757", "12084801", "24578458", "31574510", "35305172", "22269162", "37291702", "26080283", "32583471", "23461525", "29247073", "30045255", "24075740", "22451317", "20413854", "34871380"], "topk_titles": {"24681022": "(No title fetched)", "30087076": "(No title fetched)", "30337635": "(No title fetched)", "29507718": "(No title fetched)", "16009757": "(No title fetched)", "12084801": "(No title fetched)", "24578458": "(No title fetched)", "31574510": "(No title fetched)", "35305172": "(No title fetched)", "22269162": "(No title fetched)", "37291702": "(No title fetched)", "26080283": "(No title fetched)", "32583471": "(No title fetched)", "23461525": "(No title fetched)", "29247073": "(No title fetched)", "30045255": "(No title fetched)", "24075740": "(No title fetched)", "22451317": "(No title fetched)", "20413854": "(No title fetched)", "34871380": "(No title fetched)"}, "gold_ideal": ["No, there is no strong evidence to suggest that statin use is associated with a higher risk of dementia. In fact, some studies have found that statin use may be linked to a reduced risk of dementia, particularly among patients with stroke. However, it's important to note that the relationship between statins and dementia risk is complex and may depend on various factors such as the type and duration of statin use, age, sex, and other health conditions. Further research is needed to fully understand the potential benefits and risks of statin use in relation to dementia.", "According to a systematic review and meta-analysis of observational studies, statin use is not associated with a higher risk of dementia or Alzheimer's disease. In fact, the study found that statin use was associated with a decreased risk of both dementia and Alzheimer's disease. This reduction in risk was similar for both lipophilic and hydrophilic statins, but high-potency statins showed a greater efficacy in reducing dementia risk compared to low-potency statins. These findings suggest that statin treatment does not carry a neurocognitive risk and may even have a potential favorable role in reducing the risk of dementia. However, randomized clinical trials are needed to further explore this potential neuroprotective effect."], "gold_exact": ["yes"]}
{"id": "663014c8187cba990d000020", "question": "What is Alzheimer's disease?", "answer": "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [37488880] This neurodegenerative disorder is the most common cause of progressive dementia in the elderly [29441009] Based on the evidence provided, Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [23861639]", "pmids": ["37488880", "29441009", "23861639"], "pmid_titles": {"37488880": "(No title fetched)", "29441009": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins."}, "topk_used": ["37943150", "37488880", "36281662", "29441009", "38075821", "38021811", "24434253", "22009441", "27358062", "35558050", "24132372", "29298722", "37264659", "37556728", "23861639", "20826658", "21715616", "29574591", "28435465", "32183348"], "topk_titles": {"37943150": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "29441009": "(No title fetched)", "38075821": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "22009441": "(No title fetched)", "27358062": "(No title fetched)", "35558050": "(No title fetched)", "24132372": "Amyloid and neurodegeneration: converging and diverging paths.", "29298722": "(No title fetched)", "37264659": "(No title fetched)", "37556728": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "29574591": "(No title fetched)", "28435465": "(No title fetched)", "32183348": "(No title fetched)"}, "gold_ideal": ["Alzheimer's disease is a neurodegenerative disorder characterized by amyloid beta plaque and neurofibrillary tangles.", "Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid beta plaque and neurofibrillary tangles in the brain.", "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease.", "Alzheimer's disease is a neurodegenerative disorder. It's characterized by the accumulation of amyloid beta plaque and neurofibrillary tangles in the brain, leading to memory loss and cognitive decline", "Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid in the brain, leading to memory loss and cognitive decline"], "gold_exact": []}
{"id": "67faf34018b1e36f2e00010a", "question": "Have high values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol been associated with increased dementia risk in late life?", "answer": "Question: Are high values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol associated with increased dementia risk in late life? [19153372] : [19153372] Low neuroticism in combination with high extraversion is the personality trait associated with the lowest dementia risk; however, among socially isolated individuals even low neuroticism alone seems to decrease dementia risk [25274849] [19153372] High neuroticism has been associated with a greater risk of dementia, and an active/socially integrated lifestyle with a lower risk of dementia [32583471]", "pmids": ["19153372", "25274849", "32583471"], "pmid_titles": {"19153372": "Personality and lifestyle in relation to dementia incidence.", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "32583471": "(No title fetched)"}, "topk_used": ["25274849", "17244848", "23567438", "27300264", "15783264", "27358062", "37905874", "21427641", "16974109", "30045255", "19549280", "32583471", "24075740", "22269162", "29441009", "34315986", "23461525", "20413854", "19153372", "23040035"], "topk_titles": {"25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "17244848": "Chronic distress, age-related neuropathology, and late-life dementia.", "23567438": "(No title fetched)", "27300264": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "27358062": "(No title fetched)", "37905874": "(No title fetched)", "21427641": "(No title fetched)", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "30045255": "(No title fetched)", "19549280": "(No title fetched)", "32583471": "(No title fetched)", "24075740": "(No title fetched)", "22269162": "(No title fetched)", "29441009": "(No title fetched)", "34315986": "(No title fetched)", "23461525": "(No title fetched)", "20413854": "(No title fetched)", "19153372": "Personality and lifestyle in relation to dementia incidence.", "23040035": "(No title fetched)"}, "gold_ideal": ["Low values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have all been associated with increased dementia risk in late life,", "Yes, high values of blood pressure, body mass index (BMI), and non- high-density lipoprotein (HDL) cholesterol have been associated with increased dementia risk in late life.", "No, low values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have been associated with increased dementia risk in late life.", "No, studies have shown that low values for systolic blood pressure (SBP), BMI, and non-HDL cholesterol are associated with higher dementia risk in late life.", "No. The documents indicate that low values of blood pressure, BMI, and non-HDL cholesterol are associated with increased dementia risk, but there is no mention of high values being linked to increased risk.", "No, high values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have not been associated with increased dementia risk in late life.", "Yes, high values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have been associated with increased dementia risk in late life.", "Research suggests that high values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol in late life have been associated with increased dementia risk. These cardiovascular risk factors may contribute to the development of dementia, highlighting the importance of managing them to reduce the risk of cognitive decline.", "No. Low values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have been associated with increased dementia risk in late life, not high values.", "No. The provided documents focus on low values of blood pressure, BMI, and non-HDL cholesterol in relation to increased dementia risk, rather than high values.", "No. The provided documents discuss low values of blood pressure, BMI, and non-HDL cholesterol being associated with increased dementia risk, but do not mention high values of these factors in relation to dementia risk.", "No. The provided documents indicate that low values of blood pressure, BMI, and non-HDL cholesterol are associated with increased dementia risk, not high values.", "No, high values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have not been directly associated with an increased risk of dementia in late life based on the provided information. Instead, research has highlighted that low values of these parameters might be linked to an elevated risk of developing dementia as individuals age. Specifically, a study has investigated the association of low blood pressure, low BMI, and low non-HDL cholesterol with the risk of late-life dementia (PMID 35918162). The findings suggest a potential inverse relationship, where lower values rather than higher values of these measures could be of concern in the context of dementia risk. This challenges the common perception that higher levels of these parameters universally contribute to increased health risks, including dementia. Therefore, it is crucial to consider both extremes of these measurements in the assessment and management of dementia risk. Further research is needed to fully understand the implications of these findings and to explore the mechanisms underlying these associations.", "No, high values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have not been consistently associated with increased dementia risk in late life across the reviewed studies. In fact, some studies suggest that low values of these factors may be associated with increased dementia risk, highlighting the complexity of these relationships in late life.", "No. Low values of blood pressure, body mass index (BMI), and non-high- density lipoprotein (HDL) cholesterol have all been associated with increased dementia risk in late life.", "No,the context provided indicates that low values of blood pressure, BMI, and non HDL cholesterol are associated with an increased risk of dementia in late life. It does not mention high values being linked to such risks. Therefore, based on the given information, high values of these factors have not been associated with an increased dementia risk.", "No. Low levels of blood pressure, lower BMI, and lower HDL cholesterol have all been associated with an increased risk for dementia.", "No, low values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have all been associated with increased dementia risk in late life.", "No. The snippets indicate that it is lower values of blood pressure, BMI, and non-HDL cholesterol that have been associated with increased dementia risk in late life, rather than high values.", "No, low values of blood pressure, BMI, and non-HDL cholesterol have been associated with increased dementia risk in late life.", "No. High values of blood pressure, BMI, and non-HDL cholesterol are not associated with increased dementia risk in late life; rather, lower values of these factors have been linked to increased dementia risk.", "No. In late life, increased dementia risk is associated with low values of blood pressure, BMI, and non-HDL cholesterol, not high values.", "No. Low values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have all been associated with increased dementia risk in late life.", "High values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol in midlife are risk factors for dementia in late life. However, low values of these factors have been associated with increased dementia risk in late life.", "No. High values of blood pressure, BMI, and non-HDL cholesterol are not associated with increased dementia risk in late life; rather, low values of these factors have been linked to higher dementia risk.", "No. Low values of blood pressure, body mass index (BMI), and non- high-density lipoprotein (HDL) cholesterol have all been associated with increased dementia risk in late life.", "No. The documents indicate that low values of blood pressure, BMI, and non-HDL cholesterol are associated with increased dementia risk, but do not mention high values being studied together in relation to dementia risk.", "No. The documents indicate that low values of blood pressure, BMI, and non-HDL cholesterol are associated with increased dementia risk, but do not mention high values of these factors being studied together in relation to dementia risk.", "No, low values of blood pressure, body mass index (BMI), and non high density lipoprotein (HDL) cholesterol have all been associated with increased dementia risk in late life.", "Low values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have all been associated with increased dementia risk in late life.", "No, according to the provided texts, low values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have been associated with increased dementia risk in late life. In contrast, high values of these factors are typically considered cardiometabolic risk factors that increase the risk of dementia.", "Studies have shown that low values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol are associated with increased dementia risk in late life. In contrast, high values of these factors in midlife are considered risk factors for dementia. However, studies assessing combinations of late-life low values for systolic blood pressure, BMI, and non-HDL cholesterol found that individuals with low values for these risk factors have a higher dementia risk compared to those without any low values. Dementia risk was substantially higher in individuals with low values for all three risk factors than expected based on a dose-response relationship, suggesting an overarching phenomenon involving multiple risk factors simultaneously. Studies also found that cognitive decline precedes declines in total cholesterol levels, HDL cholesterol levels, and blood pressure in old age, possibly due to brain lesions affecting metabolic and blood pressure regulation centers.", "No. In late life it is low rather than high blood pressure, BMI and non-HDL cholesterol that have been linked to increased dementia risk.", "No, according to the provided snippets, it is low values of blood pressure, BMI, and non-HDL cholesterol in late life that have been associated with increased dementia risk, not high values.", "While traditionally considered risk factors, studies show that *low* values of blood pressure, BMI, and non-HDL cholesterol are actually associated with increased dementia risk in late life, despite obesity, hypercholesterolaemia and hypertension in midlife being considered risk factors. Cognitive decline may even precede changes in these vascular risk factors.", "No, high values of blood pressure, body mass index (BMI), and non-high-density lipoprotein (HDL) cholesterol have not been associated with increased dementia risk in late life. In fact, low values of these factors have been associated with increased dementia risk in late life."], "gold_exact": ["no"]}
{"id": "67f8f45518b1e36f2e000108", "question": "What proteins are measured in a blood test for Alzheimers disease?", "answer": "Platelets are the most important source of circulating forms of the amyloid precursor protein and other important proteins such as Tau and glycogen synthase kinase-3B, according to the evidence presented in the given material [24175175] These proteins are involved in the accumulation of key Alzheimer disease proteins such as hyperphosphorylated tau that ultimately prevent normal neuronal function and lead to disease symptomatology [26258756] The results suggest a basic defect in Alzheimer disease may be the reduced microRNA-driven increased expression of proteins that may alter the apoptotic/antiapoptotic balance of neurons [8180825]", "pmids": ["24175175", "26258756", "8180825"], "pmid_titles": {"24175175": "(No title fetched)", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels."}, "topk_used": ["23624169", "24633805", "37943150", "37556728", "8726460", "17883890", "21971452", "24175175", "14572915", "22472873", "19363993", "29441009", "19278690", "8180825", "17182990", "21487536", "24434253", "25783987", "19228370", "26258756"], "topk_titles": {"23624169": "(No title fetched)", "24633805": "(No title fetched)", "37943150": "(No title fetched)", "37556728": "(No title fetched)", "8726460": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "21971452": "(No title fetched)", "24175175": "(No title fetched)", "14572915": "(No title fetched)", "22472873": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "21487536": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "25783987": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease."}, "gold_ideal": ["Diagnosis of Alzheimers disease typically involves invasive and costly methods like neuroimaging or cerebrospinal fluid (CSF) biomarker testing of phosphorylated tau (p-tau) and amyloid-\u03b242/40 (A\u03b242/40) as well as neurofilament light (NfL) and glial fibrillary acidic protein (GFAP)", "The proteins measured in a blood test for Alzheimer's disease include amyloid \u03b2, P-tau217, total tau (T-tau), brain-derived tau (BD-tau), neurofilament light (NFL), and glial fibrillary acidic protein (GFAP). These biomarkers help in identifying Alzheimer's disease pathophysiology and guiding clinical management.", "Plasma biomarkers for Alzheimer's disease include A\u03b242, A\u03b240, p-tau, t-tau, neurofilament light chain, and others.", "A\u03b242, NfL, T-tau, P-tau, NT1 tau, and pTau217 are measured in a blood test for Alzheimer's disease.", "Proteins measured in blood tests for Alzheimer's disease include amyloid-beta (A\u03b2) peptides, tau, phosphorylated tau (p-tau), neurofilament light chain (NfL), and Apolipoprotein E (ApoE). Specifically, plasma p-tau217 is highlighted as having strong relationships with Alzheimer's disease outcomes and accurately classifying amyloid and tau status.", "The proteins measured in a blood test for Alzheimer's disease include NT1 tau and neurofilament light chain (NfL).", "The proteins measured in a blood test for Alzheimer's disease include amyloid-\u03b2 (A\u03b2) fragments, phosphorylated tau (P-tau), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP).", "Proteins that are measured in a blood test for Alzheimer's disease include NT1 tau, neurofilament light chain (NfL), total tau, and A\u03b242.", "Based on the provided context, the proteins measured in a blood test for Alzheimer's disease include:\n\n1. Amyloid beta-42 (A\u03b2-42)\n2. Phosphorylated tau (P-tau)\n3. Neurofilament light (NFL)\n4. ADAM10\n5. Glial fibrillary acidic protein (GFAP)\n6. Phospho-tau181 (pT181-Tau)\n7. Tau proteins\n8. Neurofilament light chain (Nf-L)\n9. Amyloid beta-40\n10. Neurofilament light chain (NFL)", "A blood test for Alzheimer's disease measures amyloid \u03b2, total-tau, phosphorylated tau, and neurofilament light proteins.", "The proteins measured in a blood test for Alzheimer's disease include: phosphorylated tau (p-tau217), amyloid-\u03b2 (A\u03b2) 42, amyloid-\u03b2 40 (A\u03b2 40), and glial fibrillary acidic protein (GFAP). These proteins are used to assess amyloid pathology and tau tangles associated with Alzheimer's disease.", "Based on the provided abstracts, several proteins have been identified as potential biomarkers for Alzheimer's disease (AD) in blood tests. These include:\n\n1. Amyloid-\u03b2 peptides (A40 and A42)\n2. Tau protein (total and phosphorylated, including tau231)\n3. Amyloid-\u03b2 variants\n4. Transthyretin\n5. \u03b1-Synuclein\n6. TDP-43\n7. NCAM1\n8. pTau231\n9. Matrix metalloproteinase 2 (MMP2)\n10. Cortisol\n11. Pancreatic polypeptide\n12. Insulin-like growth factor binding protein 2 (IGFBP2)\n13. \u03b22-Microglobulin\n14. Vascular cell adhesion molecule 1 (VCAM-1)\n15. Carcinoembryonic antigen (CEA)\n16. CD40\n17. Macrophage inflammatory protein 1 (MIP-1)\n18. Superoxide dismutase\n19. Homocysteine\n20. Apolipoprotein E\n21. Epidermal growth factor receptor (EGFR)\n22. Hemoglobin\n23. Calcium\n24. Zinc\n25. Interleukin 17 (IL-17)\n26. Albumin\n27. Prosaposin\n28. Phospholipase D1\n29. Biliverdin reductase B\n30. S100 calcium binding protein A7\n31. Heme oxygenase-1\n32. Biliverdin reductase A\n33. P2X7\n34. TNAP\n\nPlease note that this list may not be exhaustive, and the specific proteins measured in a blood test for AD may vary depending on the testing protocol and laboratory.", "The proteins measured in blood tests for Alzheimer's disease include: amyloid beta (A\u03b2)-40, amyloid beta (A\u03b2)-42, phosphorylated tau (pTau), total tau (tTau), serum neurofilament light (NFL), and glial fibrillary acidic protein (GFAP).", "Proteins measured in a blood test for Alzheimer's disease include glial fibrillary acidic protein (GFAP), S100 protein, amyloid-\u03b2 protein, and tau protein.", "The proteins measured in a blood test for Alzheimer's disease include: plasma phosphorylated tau at threonine 181 (p-tau181), plasma amyloid-\u03b2 (A\u03b2) fragments (A\u03b240 and A\u03b242), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP).", "In a blood test for Alzheimer's disease, proteins such as amyloid beta 42, tau proteins, and neurofilament light chain are measured.", "The proteins measured in a blood test for Alzheimer's disease include: p-tau181, p-tau217, p-tau231, amyloid-\u03b2 (A\u03b2)40, amyloid-\u03b2 (A\u03b2)42, total tau, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP).", "The proteins measured in a blood test for Alzheimer's disease include sLRP1, KLK4, GSN, Caspase 3, NCAM1, pTau231, \u03b1-synuclein, TDP-43, Amyloid beta, Apolipoprotein E, Fibrinogen alpha chain precursor, Keratin type I cytoskeletal 9, Serum albumin precursor, SPARC-like 1 protein, Tetranectin, pTau217, Neurofilament light chain (Nfl), and Glial fibrillary acid protein (GFAP).", "Plasma biomarkers for Alzheimer's disease include A\u03b242, p-tau217, BDNF, AGT, IGFBP-2, OPN, cathepsin D, SAP, complement C4, and prealbumin (transthyretin, TTR).", "The proteins measured in a blood test for Alzheimer's disease include glial fibrillary acidic protein (GFAP), S100 protein, and amyloid-\u03b2 protein. These biomarkers are used for identifying Alzheimer's disease and assessing its progression.", "Based on the provided context, the proteins measured in a blood test for Alzheimer's disease include:\n\n1. Amyloid beta-42 (A\u03b2-42)\n2. Phosphorylated tau (P-tau)\n3. Neurofilament light (NFL)\n4. Glial fibrillary acidic protein (GFAP)\n5. ADAM10\n6. Phospho-tau181 (pT181-Tau)\n\nAdditionally, other biomarkers mentioned in the context include:\n\n1. Apolipoprotein E (APOE) \u03b54 allele\n2. Amyloid-\u03b2 peptides\n3. Metallobiology\n4. Cystatin C (CST-C)\n5. Phospho-tau181 (pT181-Tau)\n6. Neurofilament light (NFL)\n7. Glial fibrillary acidic protein (GFAP)\n8. Phosphorylated tau (P-tau181)\n\nThese proteins are measured in blood samples using various techniques such as mass spect", "A blood test for Alzheimer's disease measures the levels of Amyloid beta-Peptides and tau Proteins in the blood.", "Blood tests for Alzheimer\u2019s disease typically measure circulating amyloid\u2011\u03b2 peptides (notably A\u03b240 and A\u03b242, often expressed as an A\u03b242/40 ratio) alongside total tau and phosphorylated tau isoforms (for example p\u2011tau181, p\u2011tau217 and p\u2011tau231). Some assays also quantify neurodegeneration and glial injury markers such as neurofilament light chain and glial fibrillary acidic protein.", "Proteins commonly measured in a blood test for Alzheimer's disease include Amyloid beta (A\u03b242, A\u03b240), Tau protein (various forms), Neurofilament light (NfL), and Glial fibrillary acidic protein (GFAP), with other proteins like sLRP1, GSN, KLK4, Caspase 3, and others being explored in specific studies.", "Proteins that are measured in a blood test for Alzheimer's disease include NT1 tau, neurofilament light chain (NfL), and amyloid beta 42 (A\u03b242).", "Based on the given context, several proteins are measured in a blood test for Alzheimer's disease, including:\n\n1. Amyloid beta-42 (A\u03b2-42)\n2. Total tau protein\n3. Phosphorylated tau species\n4. Neurofilament light (NFL)\n5. A\u03b21-42/A\u03b21-40 ratio\n6. Phospho-tau181 (pT181-Tau)\n7. ADAM10\n8. sAPP\u03b1 and \u03b2\n9. Neurogranin\n10. Unfolded p53\n11. GSK3B\n12. PTGS2\n13. APOE\n14. BACE1\n15. PSEN1\n16. TREM2\n17. GFAP (glial fibrillary acidic protein)\n18. Neurofilament light chain (NfL)\n19. Chitinase 3-like 1 protein (YKL-40)\n20. NT1\n\nThese proteins", "The proteins measured in a blood test for Alzheimer's disease are phosphorylated tau (p-tau) 181, amyloid-beta (A\u03b2) 42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL), collectively aiding in diagnosis and differentiation through their associations with neurodegeneration, amyloid positivity, astrocyte activation, and axonal injury.", "The proteins that are measured in a blood test for Alzheimer's disease include phosphorylated tau (p-tau) and neurofilament, as mentioned in the provided snippets. These proteins are important biomarkers for the diagnosis and progression of Alzheimer's disease.", "The blood test for Alzheimer's disease measures proteins such as phosphorylated tau (P-tau181), amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).", "Proteins measured in blood tests for Alzheimer's disease include amyloid-beta (A\u03b2) peptides, phosphorylated-tau (p-tau), total tau (t-tau), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and Apolipoprotein E (ApoE). Specifically, p-tau isoforms like p-tau181 and p-tau217 are showing promise for early detection and diagnosis. The ratio of A\u03b242/40 is also considered.", "The blood test measures several proteins including phosphorylated tau (P-tau181), amyloid-beta (Abeta42/40), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) to aid in Alzheimer\u2019s disease assessment.", "The proteins measured in a blood test for Alzheimer's disease include neurofilament light (NfL), glial fibrillary acidic protein (GFAP), phosphorylated tau181, and amyloid-beta (A\u03b2)42/40.", "The proteins measured in a blood test for Alzheimer's disease include: phosphorylated tau (p-tau181), amyloid-beta (A\u03b242/40), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).", "In a blood test for Alzheimer's disease, the following proteins are typically measured:\n\n1. **Phosphorylated Tau (P-tau181)**: This protein is a marker of neuronal damage and is associated with tau pathology in Alzheimer's disease.\n\n2. **Amyloid-beta 42/40 (Abeta42/40)**: These amyloid proteins are indicative of amyloid plaques, which are a hallmark of Alzheimer's disease.\n\n3. **Glial Fibrillary Acidic Protein (GFAP)**: This protein is a marker of astroglial activation and neuroinflammation, often elevated in neurodegenerative diseases like Alzheimer's.\n\n4. **Neurofilament Light (NfL)**: A neuronal filament protein that increases in the blood due to axonal damage, serving as a marker of neurodegeneration.\n\nThese biomarkers help in assessing disease progression and aiding in the diagnosis of Alzheimer's disease.", "Neurofilament light (NfL), glial fibrillary acidic protein (GFAP), Abeta42/40, and phosphorylated tau181 are measured in a blood test for Alzheimer's disease.", "Blood tests for Alzheimer\u2019s disease measure phosphorylated tau (p-tau181), the amyloid-\u03b242/40 ratio, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL).", "The blood test measures proteins including phosphorylated tau (P-tau181), amyloid-beta (Abeta42/40), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) for Alzheimer's disease.", "In order to diagnose Alzheimer's Disease (AD) in a simple blood test, researchers have developed a new blood test that measures levels of phosphorylated tau proteins (phosphorylated tau181), amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).", "Proteins measured in a blood test for Alzheimer's disease include phosphorylated tau (P-tau181), amyloid-beta (A\u03b2)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).", "The proteins measured in a blood test for Alzheimer's disease include phosphorylated tau (p-tau181), amyloid-beta (A\u03b242/40), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).", "The proteins measured in a blood test for Alzheimer's disease include phosphorylated tau 181 (pTau181), amyloid-beta 42 (Abeta42), amyloid-beta (Abeta), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). These proteins are used to help diagnose Alzheimer's disease, a progressive brain disorder that causes memory loss, cognitive decline, and changes in behavior. While traditional methods for diagnosing Alzheimer's disease involve invasive and costly methods like neuroimaging or cerebrospinal fluid (CSF) biomarker testing, recent advancements have led to the development of multimarker blood tests for clinical dementia practice.", "The proteins measured in a blood test for Alzheimer's disease include phosphorylated tau (P-tau181), amyloid-beta (A\u03b242/40), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).", "The proteins measured in a blood test for Alzheimer's disease include phosphorylated tau (p-tau181), amyloid-beta (A\u03b242/40), glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and total tau (t-tau).", "The proteins measured in a blood test for Alzheimer's disease are phosphorylated tau, amyloid-beta, glial fibrillary acidic protein, and neurofilament light.", "The proteins measured in a blood test for Alzheimer's disease include phosphorylated tau (p-tau181, p-tau217), amyloid-beta (A\u03b242, A\u03b240), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).", "The proteins consistently measured in blood tests for Alzheimer's disease are Phosphorylated Tau (pTau181), Amyloid-Beta (A\u03b242/40), Glial Fibrillary Acidic Protein (GFAP), and Neurofilament Light (NfL). These biomarkers aid in diagnosis and monitoring, with plasma pTau181 also showing promise in predicting clinical progression.", "The proteins measured in a blood test for Alzheimer's disease include phosphorylated tau (P-tau)181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) .", "In a blood test for Alzheimer's disease, several proteins are measured as biomarkers. These include:\n\n1. Phosphorylated tau (p-tau) - specifically p-tau181\n2. Amyloid-\u03b242/40 (A\u03b242/40)\n3. Glial fibrillary acidic protein (GFAP)\n4. Neurofilament light (NfL)\n\nThese biomarkers are used to aid in the diagnosis and monitoring of Alzheimer's disease, as they are associated with the progression of the disease.", "The proteins measured in a blood test for Alzheimer's disease include:\n\n1. **Phosphorylated Tau (P-Tau)**: Specifically, phosphorylated tau at position 181 (P-tau181) is used as a biomarker.\n2. **Amyloid-beta 42/40 (A\u03b242/40)**: This ratio helps in assessing amyloid pathology.\n3. **Glial Fibrillary Acidic Protein (GFAP)**: Indicates astroglial activation, associated with neuroinflammation.\n4. **Neurofilament Light (NfL)**: Reflects axonal injury and neurodegeneration.\n\nThese biomarkers are part of a multimarker blood test used to aid in the diagnosis and monitoring of Alzheimer's disease.", "Blood tests for Alzheimer's disease primarily measure a panel of proteins including phosphorylated tau (p-tau) 181, amyloid-\u03b242/40 (A\u03b242/40), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). Notably, p-tau 181 is highlighted for its significant diagnostic and predictive value, contributing substantially to the assessment of Alzheimer's disease through these blood-based tests.", "Current blood tests quantify the amyloid-\u03b2 peptides A\u03b240 and A\u03b242 (often reported as the A\u03b242/40 ratio), total tau and phosphorylated tau species such as p-tau181, p-tau217 and p-tau231. Many assays also measure markers of neurodegeneration and glial activation, notably neurofilament light chain and glial fibrillary acidic protein.", "The proteins measured in a blood test for Alzheimer's disease are phosphorylated tau181 (p-tau181), amyloid-beta42/40 (A\u03b242/40), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).", "Blood tests for Alzheimer's disease may measure several proteins, including phosphorylated tau (p-tau) at various sites such as p-tau181 and p-tau217, amyloid-beta (A\u03b2) in different forms like A\u03b242 and A\u03b240, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). Ratios of phosphorylated to non-phosphorylated tau, and A\u03b242/A\u03b240 ratios are also assessed. Other proteins that may be included are amyloid precursor protein (APP) isoforms, cytokines, apolipoproteins such as Apolipoprotein E, iron transport protein p97, fibrinogen alpha chain precursor, keratin type I cytoskeletal 9, serum albumin precursor, SPARC-like 1 protein, tetranectin, angiogenin (ANG), and tissue inhibitor of matrix metalloproteinase-4 (TIMP-4). Total tau (t-tau) is also measured."], "gold_exact": [["phosphorylated tau (p-tau)", "pTau181"], ["amyloid-\u03b242/40 (A\u03b242/40)"], ["glial fibrillary acidic protein (GFAP)"], ["neurofilament light (NfL)."], ["PX27"], ["TNAP"]]}
{"id": "5e4b64516d0a277941000029", "question": "Is Semagacestat effective for Alzheimer's Disease?", "answer": "Yes, Semagacestat was found to be ineffective for Alzheimer's Disease in a recent negative efficacy study [26064192] The study included several biomarkers of the disease as well as safety outcomes, and the results were published in a peer-reviewed journal [23883379] While the study did not show a statistically significant improvement in cognitive status, patients receiving the higher dose experienced significant worsening of functional ability [23334070]", "pmids": ["26064192", "23883379", "23334070"], "pmid_titles": {"26064192": "(No title fetched)", "23883379": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["20154508", "27567808", "7510447", "24983746", "23883379", "15649697", "25871773", "23334070", "23624169", "22536363", "23785331", "7579023", "28978478", "21149978", "21971452", "23196551", "26064192", "21784350", "21501112", "20360050"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "23624169": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "23785331": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "28978478": "(No title fetched)", "21149978": "(No title fetched)", "21971452": "(No title fetched)", "23196551": "(No title fetched)", "26064192": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21501112": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "gold_ideal": ["No. In a placebo controlled clinical trial, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. The trial was terminated due to unexpected aggravation of cognitive deficits and side effects."], "gold_exact": ["no"]}
{"id": "6026754f1cb411341a0000c8", "question": "Should minocycline be used for mild Alzheimer disease?", "answer": "Question: Should minocycline be used for mild Alzheimer disease? [31738372] : 1 [37488880] The group comprised of 194 normal elderly, 212 early mild cognitive impairment [EMCI], 132 late mild cognitive impairment [LMCI], and 64 mild Alzheimer's (AD) [23624169]", "pmids": ["31738372", "37488880", "23624169"], "pmid_titles": {"31738372": "(No title fetched)", "37488880": "(No title fetched)", "23624169": "(No title fetched)"}, "topk_used": ["10510805", "31738372", "23334070", "20360050", "7510447", "37943150", "20154508", "21996556", "23624169", "29441009", "2107926", "21705182", "24983746", "23785331", "24633805", "35558050", "15783264", "37902139", "37490245", "37488880"], "topk_titles": {"10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "31738372": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "37943150": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "21705182": "(No title fetched)", "24983746": "(No title fetched)", "23785331": "(No title fetched)", "24633805": "(No title fetched)", "35558050": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37902139": "(No title fetched)", "37490245": "(No title fetched)", "37488880": "(No title fetched)"}, "gold_ideal": ["No. Minocycline did not delay the progress of cognitive or functional impairment in people with mild Alzheimer disease during a 2-year period."], "gold_exact": ["no"]}
{"id": "602673e91cb411341a0000c7", "question": "Is Lanabecestat effective for Alzheimer's disease?", "answer": "Yes, Lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease as shown by the APECS and AMARANTH trials [33049114] The BACE inhibitor verubecestat failed to show any benefit, while the BACE inhibitor lanabecestat was associated with treatment-related adverse events [29719179]", "pmids": ["33049114", "29719179"], "pmid_titles": {"33049114": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["23624169", "15649697", "33049114", "7579023", "29719179", "7510447", "31764959", "20154508", "30970186", "29461065", "22536363", "29397980", "24983746", "25871773", "23883379", "27567808", "31423903", "37943150", "37490245", "23785331"], "topk_titles": {"23624169": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "29719179": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "31764959": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "29397980": "(No title fetched)", "24983746": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "27567808": "(No title fetched)", "31423903": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)", "23785331": "(No title fetched)"}, "gold_ideal": ["No. Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline of Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "6057bf0694d57fd879000031", "question": "What promotes amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells?", "answer": "Question: What is the role of apoE4 fragment apoE4-165 in promoting amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells? [27476701] : 1 [32183293] We have previously shown that a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis [23293020]", "pmids": ["27476701", "32183293", "23293020"], "pmid_titles": {"27476701": "(No title fetched)", "32183293": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["27476701", "33513738", "23796662", "23293020", "32582833", "36281662", "21903360", "23528227", "36687366", "22203915", "37943150", "22110363", "19228370", "21206757", "25871773", "23378928", "20122289", "23536396", "19181896", "32183293"], "topk_titles": {"27476701": "(No title fetched)", "33513738": "(No title fetched)", "23796662": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "32582833": "(No title fetched)", "36281662": "(No title fetched)", "21903360": "(No title fetched)", "23528227": "(No title fetched)", "36687366": "(No title fetched)", "22203915": "(No title fetched)", "37943150": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "21206757": "Presenilin 2 is the predominant \u03b3-secretase in microglia and modulates cytokine release.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "23536396": "Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid.", "19181896": "(No title fetched)", "32183293": "(No title fetched)"}, "gold_ideal": ["The apolipoprotein (apo) E4 isoform is the strongest risk factor for late-onset Alzheimer's disease (AD). ApoE4 is more susceptible to proteolysis than apoE2 and apoE3 isoforms and carboxyl-terminal truncated apoE4 forms have been found in AD patients' brain. A specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis.", "The amyloid-peptide beta 42 (A\u03b242) accumulates in neuroblastoma cells due to a protein called apoE4-165, which is an apolipoprotein (APOE4). This protein is the most common protein responsible for late-onset Alzheimer disease."], "gold_exact": [["apoE4-165"]]}
{"id": "604915581cb411341a00016a", "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?", "answer": "Yes, YKL-40 is a promising candidate biomarker of glial inflammation in Alzheimer's disease [31794792] Recently, cerebrospinal fluid (CSF) YKL-40 levels were reported to be a significant predictor of cognitive decline and amnestic mild cognitive impairment (aMCI) in patients with Alzheimer's disease (AD) [17182990] These findings suggest that YKL-40 could be a valuable biomarker for early detection and monitoring of AD [32045356]", "pmids": ["31794792", "17182990", "32045356"], "pmid_titles": {"31794792": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "32045356": "(No title fetched)"}, "topk_used": ["31794792", "32045356", "19278690", "15783264", "24175175", "37943150", "8180825", "17182990", "37556728", "21705182", "21971452", "20929585", "29441009", "37490245", "22529838", "19164222", "36281662", "19881909", "21996556", "19324376"], "topk_titles": {"31794792": "(No title fetched)", "32045356": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24175175": "(No title fetched)", "37943150": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37556728": "(No title fetched)", "21705182": "(No title fetched)", "21971452": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "29441009": "(No title fetched)", "37490245": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "36281662": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection."}, "gold_ideal": ["Yes,\ncerebrospinal fluid (CSF) YKL-40 levels were reported to be a promising candidate biomarker of glial inflammation in Alzheimer's disease (AD)."], "gold_exact": ["yes"]}
